The Role of Rosuvastatin on Vascular Involvement in Behçet's Disease
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Behçet's Disease(BD) is a systemic inflammatory vasculitis, which affects all types and sizes
of vessels. Statins display numerous effects often independent of the well-established
lipid-lowering effects that may be of benefit in retarding or preventing vascular injury and
ischaemic vascular events. The aim of the present study was to determine the efficacy of
rosuvastatin in improving vascular dysfunction and vascular inflammation and to assess the
effect of rosuvastatin on vascular involvement in BD patients. Fifty-six BD patients (51
males and 5 females) mean age 33.4 years, mean disease duration 5.8 years), all fulfilling
the classification criteria of the International Study Group for Behçet's disease were
recruited.Patients were randomised into 2 groups.
The first group (n=27: 20 active and 7 inactive) were assigned to receive 40 mg of
rosuvastatin and the second group(n=29: 21 active and 8 inactive) received placebo for 12
months. Inflammatory and endothelial dysregulation markers were measured at baseline and
after 12 months. All patients were examined for vascular involvement. Venous or arterial
system involvement was defined as present when confirmed by Doppler ultrasonography, magnetic
resonance angiography, conventional angiography or CT.